The results from recent trials of oral obesity candidates have left investors underwhelmed, with Eli Lilly’s orforglipron and Viking Therapeutics’ VK2735 failing to meet expectations. Analysts predict that weight loss pills may have a larger impact in low- and middle-income countries compared to the U.S., where injected peptides currently dominate the market. Despite the anticipated growth in the anti-obesity medication market, the performance of these oral therapies raises questions about their potential game-changing impact.
While the U.S. market still favors injected peptides for maximum weight loss, oral weight loss therapies could find their niche in regions with less robust healthcare infrastructure, where the convenience of oral administration without the need for refrigeration could be a significant advantage. However, the recent efficacy results from Lilly’s orforglipron and Viking’s VK2735 have fallen short of the benchmark set by Novo Nordisk’s subcutaneous Wegovy, indicating a need for improved performance to compete effectively in the market.
The comparison between these oral candidates is complex due to the differences in their molecular structures, with orforglipron being a small molecule and oral Wegovy and VK2735 being peptides. Analysts have noted that the manufacturing processes for small molecules like orforglipron may offer cost advantages over peptides, but the clinical profile and efficacy of the treatments will ultimately drive market adoption. Novo’s Wegovy has demonstrated promising results, with an average reduction in body weight of 16.6% in pill form, positioning the company as a strong contender in the oral weight loss market.
One of the key considerations in the evaluation of oral obesity treatments is their tolerability profile, as well as the duration of treatment and the impact of factors like food intake on efficacy. Novo’s confidence in addressing these challenges and delivering a successful oral weight loss product highlights the company’s strategic position in the market. The upcoming data releases from Structure Therapeutics and the future regulatory submissions from Novo and Eli Lilly will provide further insights into the evolving landscape of oral obesity treatments.
As Novo advances towards potential FDA approval for oral Wegovy and Lilly prepares to submit regulatory applications for orforglipron, the competition in the oral weight loss market is intensifying. With Novo’s strong performance and strategic initiatives, including the development of additional oral treatments, the company is well-positioned to lead the pack in oral obesity therapies. The market dynamics and patient and physician reactions to these new treatments will ultimately shape the future of oral weight loss therapies and their impact on the broader obesity treatment landscape.
- Novo Nordisk emerges as a leader in the oral weight loss market, with promising efficacy results for Wegovy.
- The competition between oral obesity treatments hinges on factors like molecular structure, manufacturing costs, tolerability, and treatment duration.
- Market dynamics in different regions, including low- and middle-income countries, will influence the adoption of oral weight loss therapies.
- Future data releases and regulatory submissions will provide further insights into the performance and potential of oral obesity treatments.
Tags: regulatory, formulation
Read more on biospace.com